Abstract:Abstract Background TAVR has become the standard of care for high–risk patients with aortic stenosis. Considering unique procedural challenges posed by native pure aortic regurgitation (NPAR), our aim was to evaluate early and mid–term results of off–label treatment with new generation devices. Materials and Methods We retrospectively enrolled 61 consecutive patients, who underwent TAVR for NPAR between 2017 and 2023, because deemed ineligible for surgery. Mean logistic and Euroscore II were 17,07±11 and 5,62±5,9, though they did not accurately reflect surgical ineligibility: 7 patients (11,5%) had active cancer and 5 (8,2%) end–stage liver failure. Patients with valve calcifications or stenosis were excluded. A CT scan was obtained to choose device model and size, and access site. A percutaneous VA ECMO support was used in patients at higher risk for hemodynamic instability and procedural failure. Local anesthesia was preferred whenever feasible. Primary endpoints were technical and device success. Secondary endpoint was clinical efficacy at 1 year. Results Mean age was 75,69±9,01. Considering the high–risk population, we adopted local anesthesia in 56 patients (91,8%), reducing ICU admission and stay (27,9% and 1,98±6,51days). Mean aortic annulus diameter, perimeter and area were 25,5±2,16mm, 82,2±5,84mm and 520,04±74,32mm2. Consequently, the most frequently implanted prostheses were Evolut R/Pro 34 (41%), Sapien 3/Ultra 29 (26,2%) and Accurate neo M (9,8%). Approximately half of the population (54,1%) was shortly supported (24,46±24,7 minutes) with fem–fem VA ECMO, reducing hemodynamic instability due to rapid pacing. However, no increase in vascular complication was observed (p=0,58). One intraprocedural death was recorded (1,6%). Although 30–day mortality was 8,2%, primary outcomes were significantly better in the second half of the population (p=0,044 and p=0,036), reflecting the role of a standardized approach and surgeons’ higher expertise. Only 4 paravalvular leaks (6,6%) were detected at 1–month follow–up, 3 mild and 1 moderate (1,6%). Mean follow–up was 18,54±18,48 months. Clinical efficacy at 1 year was 76,3%, available for 38 patients. Conclusions TAVR is still considered an off–label approach for NPAR because of increased stroke volume and absence of annular and leaflet calcification. Nonetheless a standardized approach, with the aid of brief VA ECMO support for complex cases, should be considered a safe and valid option for inoperable patients.

[Prosthetic valve endocarditis: current problems].

Multicenter Comparison of Percutaneous and Surgical Pulmonary Valve Replacement in Large RVOT.

Transcatheter pulmonary valve replacement in surgically‐created double‐barrel right ventricular outflow tracts: A single center case‐series

Early Outcomes From a Multicenter Transcatheter Self-Expanding Pulmonary Valve Replacement Registry

Right Heart Reverse Remodeling and Prosthetic Valve Function After Transcatheter vs Surgical Pulmonary Valve Replacement

Transcatheter Tricuspid and Pulmonary Valve Repair and Replacement

Pulmonary Valve Replacement in Primary Repair of Tetralogy of Fallot in Adult Patients

Impairment of fat oxidation under high- vs. low-glycemic index diet occurs before the development of an obese phenotype.

Impact of pulmonary stenosis on right ventricular global longitudinal strain in repaired tetralogy of Fallot patients post transcatheter pulmonary valve replacement

Editorial Comment to Clinical outcome analysis of male and female genital burn injuries: A 15‐year experience at a Level‐1 Burn Center

Is there a role for endovascular stent implantation in the management of postoperative right ventricular outflow tract obstruction in the era of transcatheter valve implantation?

[A case report of a scalp dermoid cyst containing watery-clear fluid].

TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak

A Study on Mechanical Properties of Fiberboard Made of Durian Rind through Latex with Phenolic Resin as Binding Agent

The best way to prevent cytomegalovirus infection after liver transplantation: the debate goes on

Finite element modeling with patient‐specific geometry to assess clinical risks of percutaneous pulmonary valve implantation

SAFETY AND EFFICACY OF TRANSCATHETER AORTIC VALVE REPLACEMENT FOR NATIVE PURE AORTIC VALVE REGURGITATION: SINGLE–CENTER EXPERIENCE

Intentional Oversizing of Valve in Transcatheter Aortic Valve Replacement: Is Bigger Better? A Large, Single-Center Experience

Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project

A Self-Expanding Percutaneous Valve for Patients with Pulmonary Regurgitation and an Enlarged Native Right Ventricular Outflow Tract: One-Year Results

Simulation of left ventricular outflow tract (LVOT) obstruction in transcatheter mitral valve-in-ring replacement